Affymetrix (Santa Clara, California) (AFFX) Signs Contract With UK Biobank to Genotype 500,000 UK Individuals in the Largest Ever Study of Genetic and Environmental Factors in Disease and Personalized Medicine
3/22/2013 9:36:23 AM
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has signed a contract with UK Biobank to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health. Affymetrix’ Axiom® Genotyping Solution will be used to generate billions of high-quality genotypes which will provide UK Biobank and the research community with valuable insight to genetic factors underlying human diseases for improved prevention, diagnosis, and treatment of conditions such as heart disease, cancer, and diabetes.
comments powered by